Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor <scp>ECOG</scp> Performance Status With Relapsed or Refractory Large B‐Cell Lymphoma After 2 or More Lines of Prior Therapy” - KIVIRID

Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor <scp>ECOG</scp> Performance Status With Relapsed or Refractory Large B‐Cell Lymphoma After 2 or More Lines of Prior Therapy”

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27551

Keywords:

Abstract:

Source: